India Bladder Cancer Market 2026-2035

India Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)

Industry Overview

India bladder cancer market was valued at $153.1 million in 2025 and is projected to reach $278.0 million by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). The India bladder cancer market is expanding steadily, driven by the rising incidence of urothelial carcinoma and other bladder cancer types across urban and semi-urban populations. Improved diagnostic capabilities, including cystoscopy, biopsy, urine cytology, and advanced imaging techniques, have enhanced early detection rates and increased treatment uptake. Growing awareness initiatives and screening programs are further encouraging timely diagnosis and clinical intervention. Advancements in therapeutic modalities such as immunotherapy, targeted chemotherapy, and minimally invasive surgical procedures are strengthening treatment outcomes and market demand. Additionally, increasing healthcare expenditure and the expansion of specialized oncology centers across India are supporting wider access to bladder cancer care. Strategic collaborations between domestic and international pharmaceutical companies are also contributing to innovation and sustained market growth through 2026–2035.

Market Dynamics

Rising Adoption of Advanced Diagnostic Techniques

The market is witnessing a significant shift toward advanced diagnostic methods such as cystoscopy, urine cytology, and intravenous pyelogram (IVP), which enable early and accurate detection of bladder cancer. Increasing availability of minimally invasive diagnostic tools in urban healthcare centers is driving patient preference for early-stage screening. This trend is further supported by government-led awareness campaigns and routine screening programs targeting high-risk populations. Enhanced diagnostic precision is leading to timely clinical intervention, improving overall patient outcomes. As technology adoption expands, smaller cities and regional hospitals are gradually incorporating these methods. Consequently, the demand for diagnostic solutions is expected to grow consistently through 2035.

Expansion of Specialized Oncology Infrastructure

The proliferation of specialized cancer centers and dedicated urology departments is enhancing accessibility to comprehensive bladder cancer care across India. Urban and semi-urban regions are witnessing the establishment of state-of-the-art hospitals equipped with advanced diagnostic and therapeutic facilities. Collaborations between domestic and international healthcare providers are facilitating technology transfer and knowledge sharing, improving treatment quality. Additionally, rising healthcare expenditure and insurance coverage are enabling more patients to seek timely treatment. This infrastructural growth is expected to sustain market momentum and support increased adoption of both conventional and innovative therapies through 2035.

Market Segmentation

• Based on the cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others.
• Based on the diagnosis method, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology and intravenous pyelogram and others.
• Based on the treatment, the market is segmented surgery, chemotherapy, immunotherapy, radiation therapy and others.

Urothelial Carcinoma Emerging as the Leading Driver of Bladder Cancer Market Growth

Transitional cell bladder cancer, also known as urothelial carcinoma, represents the largest segment in India’s bladder cancer landscape, fueled by its high prevalence among adult populations. Rising incidence rates, coupled with early detection through advanced diagnostic techniques, are driving significant market growth. Key players, including Novartis, Pfizer, and Cipla, are focusing on innovative chemotherapy and immunotherapy solutions to improve patient outcomes. Recent trends indicate a shift toward combination therapies and personalized treatment regimens, enhancing efficacy and reducing recurrence. Strategic collaborations between hospitals and pharmaceutical firms are expanding access to targeted therapies in urban and semi-urban regions. Continuous investment in clinical trials is expected to sustain long-term growth through 2035.

Cystoscopy Transforming Early Detection and Diagnosis of Bladder Cancer in India

Cystoscopy remains the fastest-growing diagnostic subsegment, driven by its accuracy in detecting early-stage bladder malignancies. Increasing awareness among urology specialists and patients about minimally invasive procedures has accelerated adoption in both private and public healthcare facilities. Key market contributors such as Olympus, Boston Scientific, and Stryker are introducing flexible and high-definition scopes to enhance patient comfort and procedural efficiency. Recent trends include integration with digital imaging and AI-assisted diagnostics, improving detection rates and reducing procedural time. Government initiatives promoting routine screening are also supporting market penetration in tier-2 and tier-3 cities. As a result, cystoscopy is projected to maintain rapid growth and significant market influence through 2035.

Market Players Outlook

The major companies operating in the India bladder cancer market include Astellas Pharma India Pvt. Ltd., Bristol-Myers Squibb India Pvt. Ltd., MSD Pharmaceuticals Pvt. Ltd., Pfizer India Pvt. Ltd. and Roche Products (India) Pvt. Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, AstraZeneca Pharma India received approval from the Central Drugs Standard Control Organisation (CDSCO) for Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant therapy, followed by single-agent Durvalumab as adjuvant treatment after radical cystectomy for adult patients with muscle-invasive bladder cancer (MIBC). The approval is based on results from the Phase III NIAGARA trial, which showed a 32% reduction in the risk of disease progression, recurrence, or death and a 25% reduction in the risk of death compared with standard treatment.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the India bladder cancer market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more